Results 121 to 130 of about 4,732 (172)
Some of the next articles are maybe not open access.

Rimonabant—A Selective CB1 Antagonist

Annals of Pharmacotherapy, 2005
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of rimonabant, a new selective cannabinoid receptor antagonist. DATA SOURCES: Primary literature and review articles were obtained via a MEDLINE ...
Steven Thomas, Boyd   +1 more
exaly   +3 more sources

Rimonabant

Drugs, 2006
Rimonabant is the first of a new class of selective cannabinoid receptor-1 blockers. It reduces the overactivity of the endocannabinoid system, improving lipid and glucose metabolism and regulating food intake and energy balance. In four randomised, double-blind clinical trials in overweight or obese adults with or without type 2 diabetes and/or ...
Sheridan, Henness   +2 more
  +6 more sources

Rimonabant

Reactions Weekly, 2009
John A. Davies, Steve P.H. Alexander
  +7 more sources

Rimonabant for overweight or obesity

Cochrane Database of Systematic Reviews, 2006
Worldwide, the prevalence of obesity and overweight in industrialized countries and in a substantial number of developing countries is increasing at an alarming rate. Rimonabant is a selective cannabinoid-1 receptor antagonist that has been investigated for its efficacy in reducing body weight and associated risk factors in obese people.
C, Curioni, C, André
openaire   +2 more sources

Rimonabant for the Treatment of Obesity

Recent Patents on Cardiovascular Drug Discovery, 2008
Obesity is a growing public health problem that is already reaching epidemic proportions and is increasingly encompassing young children and adolescents. Despite the increasing prevalence and the health risks associated with obesity, the pharmacotherapeutic options for treating obesity are limited. The endogenous cannabinoid or endocan-nabinoid system (
Ashish, Samat   +3 more
openaire   +2 more sources

Rimonabant

Reactions Weekly, 2010
Stan Floresco   +116 more
  +5 more sources

Home - About - Disclaimer - Privacy